• Mutation; VGNC; VGNC:38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468).
  

PubMed=24035468; DOI=10.1016/j.tvjl.2013.08.003
Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K., Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., Hiroi T., Yamamoto H., Ono K., Washizu T., Bonkobara M.
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Vet. J. 198:577-582(2013)

PubMed=27292541; DOI=10.1111/jvp.12336
Kuroki S., Kobayashi M., Tani H., Miyamoto R., Kurita S., Tamura K., Ono K., Washizu T., Bonkobara M.
Selective growth inhibition by suppression of F1Fo ATPase in canine malignant melanoma cell lines.
J. Vet. Pharmacol. Ther. 40:101-104(2017)

PubMed=30268330; DOI=10.1016/j.tvjl.2018.09.001
Miyamoto R., Kurita S., Tani H., Ikeda T., Ishizaka M., Saima H., Kobayashi M., Tamura K., Bonkobara M.
Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
Vet. J. 240:31-36(2018)